MyMD Pharmaceuticals Announces Issuance of Allowance from United States Patent and Trademark Office for Synthetic Cannabinoid Compounds

CANNANNEW REPORT

Patent protects Supera-CBD, a preclinical cannabidiol derivative that targets cannabinoid receptor type 2 for the treatment of neuroinflammatory and neurodegenerative… Read More…..

Excerpt only …
READ MORE BELOW
Source : MyMD Pharmaceuticals Announces Issuance of Allowance from United States Patent and Trademark Office for Synthetic Cannabinoid Compounds

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.